Research and Markets (http://www.researchandmarkets.com/research/lgvdjn/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Huntington's Disease Overview
- Therapeutics Development
- Pipeline Products for Huntington's Disease - Overview
- Pipeline Products for Huntington's Disease - Comparative Analysis
- Huntington's Disease - Therapeutics under Development by Companies
- Huntington's Disease - Therapeutics under Investigation by Universities/Institutes
- Huntington's Disease - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Huntington's Disease - Products under Development by Companies
- Huntington's Disease - Products under Investigation by Universities/Institutes
- Huntington's Disease - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- AFFiRiS AG
- Alnylam Pharmaceuticals, Inc.
- Angita B.V.
- Astellas Pharma Inc.
- Azevan Pharmaceuticals, Inc.
- BioCrea GmbH
- BioMarin Pharmaceutical Inc.
- BrainStorm Cell Therapeutics Inc.
- Chong Kun Dang Pharmaceutical Corp.
- Kadmon Corporation, LLC
- KineMed, Inc.
- Living Cell Technologies Limited
- Medesis Pharma S.A.
- Neuralstem, Inc.
- Neurimmune Holding AG
- NeuroNascent, Inc.
- New World Laboratories, Inc.
- nLife Therapeutics, S.L.
- NsGene A/S
- Provid Pharmaceuticals, Inc.
- QR Pharma, Inc.
- Raptor Pharmaceuticals Inc
- reMYND NV
- RestorGenex Corporation
- Rhenovia Pharma Limited
- Sangamo BioSciences, Inc.
- Vaccinex, Inc.
- Vertex Pharmaceuticals Incorporated
- VistaGen Therapeutics , Inc.
- VivaCell Biotechnology Espana S.L.
- Voyager Therapeutics, Inc.
- Vybion, Inc.
- Zenobia Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/lgvdjn/huntingtons
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121006138/en/
